The study is a three-arm, randomized trial which will enroll up to 180 patients at cancer centers in North America and Europe.
Charles Craddock, professor of haemato-oncology at University of Birmingham, UK, said: “Vidaza recently demonstrated a major survival benefit when used to treat patients with high-risk myelodysplastic syndromes (MDS).
“The Phase I/II data with this combination were also compelling, and we aim to determine definitively whether combination treatment is superior to monotherapy in MDS and acute myeloid leukemia.”